As a benefit for attending the 32nd Annual Meeting and Pre-Conference Programs, SITC provides enduring materials free of charge for the specific programs attended. If you are a SITC member, or member of the general public, but did not register to attend a Pre-Conference program or the 32nd Annual Meeting, the materials are available for purchase by clicking here.
Presentations and video recordings are available based on permission from presenters.
Presentations with this symbol indicate that the presenter did not grant permission to the presentation.
Wednesday, Nov. 8
|
1 – 1:05 p.m. |
Welcome & Introductions Tanja de Gruijl, PhD – VU University Medical Center Graham Pawelec, PhD – University of Tuebingen |
Cherry Blossom Ballroom |
Session I: Checkpoint Blockade
|
Senior Co-Chairs:
Beatrix Kotlan, PhD – National Institute of Oncology, Budapest Sacha Gnjatic, PhD – Cancer Research Institute (CRI) Zihai Li, MD, PhD – Chinese American Hematology Oncology Network (CAHON) Lisa H. Butterfield – Society for Immunotherapy of Cancer (SITC) Willemijn Hobo, PhD – Dutch Tumor Immunology Working Party (DTIWP)
|
1:05 – 1:10 p.m. |
Welcome & Introductions Junior Co-Chair: Hong Zheng, MD, PhD – Pennsylvania State Cancer Institute |
|
1:10 – 1:25 p.m. |
Immunotherapy - Long Term Survival Metastic Melanoma Katalin Czirbesz, MD – National Institute of Oncology, Budapest |
|
1:25 – 1:40 p.m. |
PD-1 Blockade: Understanding CD8 T Cell Rescue for Insights into Cancer Immunotherapy Alice O. Kamphorst, PhD – Cancer Research Institute (CRI) |
|
1:40 – 1:55 p.m. |
Viral-based Cancer Immunotherapy in the Era of Immune Checkpoint Blockade Liang Deng, MD, PhD – Chinese American Hematology Oncology Network (CAHON)
|
|
1:55 – 2:10 p.m. |
Treg Modulation as a Pharmacodynamic Biomarker of GITR Stimulation in Cancer Patients Roberta Zappasodi, PhD – Society for Immunotherapy of Cancer (SITC)
|
|
2:10 – 2:25 p.m. |
PD-L1 Expression on Malignant Cells is no Prerequisite for Checkpoint Therapy Jan Willem Kleinovink, PhD – Dutch Tumor Immunology Working Party (DTIWP) |
|
2:25 – 2:40 p.m. |
Break |
|
Session II: Adoptive T cell Therapy
|
Senior Co-Chairs:
Robert E. Hawkins, MD, PhD – Adoptive Engineered T Cell Targeting to Activate Cancer Killing (ATTACK) Per thor Straten, PhD – Progress in Vaccination Against Cancer (PIVAC) Pamela Ohashi, PhD – Canadian Cancer Immunotherapy Consortium (CCIC)
|
2:40 – 2:45 p.m. |
Welcome & Introductions Junior Co-Chair: Marco Ruella, MD – University of Pennsylvania |
|
2:45 – 3:00 p.m. |
Exploiting Tumor Infiltrating Lymphocytes (Tils) as a Therapeutic Strategy for Epithelial Ovarian Cancer Gemma Owens, MB, BCh – Adoptive Engineered T Cell Targeting to Activate Cancer Killing (ATTACK) |
|
3:00 – 3:15 p.m. |
Combined Killing of Cancer Cells and Cross Presentation of Tumor Antigen By Vγ9Vδ2 T Cells Gitte Holmen Olofsson, MS – Progress in Vaccination Against Cancer (PIVAC) |
|
3:15 – 3:30 p.m. |
A Novel Innate Lymphoid Cell Population Regulates Tumor-Associated T Cells Sarah Crome, PhD – Canadian Cancer Immunotherapy Consortium (CCIC) |
|
3:30 – 3:45 p.m. |
Break |
|
Session III: Innate Immunity
|
Senior Co-Chairs:
Weihua Xiao, MD, MS – Chinese Society of Immunology (CSI) and Committee for Tumor Immunology and Bio-Therapy (TIBT) Heinz Zwierzina, MD – Cancer Drug Development Forum (CDDF) Angus Dalgleish, MD, PhD – Institute for Cancer Vaccines and Immunotherapy (ICVI)
|
3:45 – 3:50 p.m. |
Welcome & Introductions Junior Co-Chair: Cheng Sun, MD, PhD – Chinese Academy of Sciences and University of Science and Technology of China |
|
3:50 – 4:05 p.m. |
Dysfunction of Dendritic Cells in Lung Cancer Fang Fang, PhD – Chinese Society of Immunology (CSI) and Committee for Tumor Immunology and Bio-Therapy (TIBT) |
|
4:05 – 4:20 p.m. |
Development of a Novel Immunotherapy with Toll-Like and Nod-Like Receptors Synergy for Targeted Cancer Therapy Celia Jacoberger-Foissac, MSc – Cancer Drug Development Forum (CDDF) |
|
4:20 – 4:35 p.m. |
Zoledronic Acid Induces Gamma Delta T Cells to Target Macrophages Daniel William Fowler, PhD – Institute for Cancer Vaccines and Immunotherapy (ICVI)
|
|
4:35 – 5:40 p.m. |
Dinner
|
|
Session IV: Novel Approaches to Improve Immunotherapy
|
Senior Co-Chairs:
Kazuhiro Kakimi, MD, PhD – Japanese Association of Cancer Immunotherapy (JACI) Barbara Seliger, MD, PhD – Tumor Immunology Meets Oncology (TIMO) Michele Maio, MD, PhD – NIBIT Foundation (Network Italiano per la Bioterapia dei Tumori) Giuseppe Masucci, MD, PhD – Scandinavian Network for Immunotherapy of Cancer (SNIC)
|
5:40 – 5:45 p.m. |
Welcome & Introductions Junior Co-Chair: Margot Pont, PhD – Fred Hutchinson Cancer Research Center |
|
5:45 – 6 p.m. |
An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Cancer Immunotherapy Takahiro Karasaki, MD – Japanese Association of Cancer Immunology (JACI) |
|
6 – 6:15 p.m. |
Reversing the Tumor Immune Escape with Selenium Claudia Lennicke, PhD – Tumor Immunology Meets Oncology (TIMO)
|
|
6:15 – 6:30 p.m. |
Epigenetic Immunomodelling to Improve the Efficacy of Cancer Immunotherapy Alessia Covre, PhD – NIBIT Foundation (Network Italiano per la Bioterapia dei Tumori)
|
|
6:30 – 6:45 p.m. |
Blood in Circulation, with Intact Cascade Systems, as a Tool to Predict First - Infusion Reactions and Mechanism of - Action of Immunotherapeutics Erika Fletcher, PhD – Scandinavian Network for Immunotherapy of Cancer (SNIC)
|
|
6:45 – 7 p.m. |
Closing Remarks Graham Pawelec, PhD – University of Tuebingen
|
|